Veracyte : Completion of Acquisition or Disposition of Assets (Form 8-K)

Completion of Acquisition or Disposition of Assets.

On August 2, 2021, Veracyte, Inc., a Delaware corporation ('Veracyte'), completed its previously announced acquisition of HalioDx SAS, a French société par actions simplifiée ('HalioDx'), for a purchase price of €260 million in total consideration to HalioDx securityholders, consisting of approximately €147 million in cash and approximately €113 million in shares of Veracyte common stock (such shares of common stock, the 'Stock Consideration'), subject to customary purchase price adjustments (the 'Acquisition').

The foregoing summary of the Acquisition, as supplemented by the Company's previously-filed Current Reports on Form 8-K dated as of June 1, 2021 and July 13, 2021 related to the Acquisition, does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Securities Purchase and Contribution Agreement, dated as of July 13, 2021, by and between Veracyte and HalioDx, which was filed as Exhibit 10.5 to Veracyte's Quarterly Report on Form 10-Q for the three months ended June 30, 2021.

Unregistered Sales of Equity Securities.

The information set forth above under Item 2.01 relating to the Stock Consideration is hereby incorporated by reference into this Item 3.02.